Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy

European Journal of Clinical Pharmacology

Volumn 50, Issue 4, 1996, Pages 249-252

  Kupfer A ^a   Aeschlimann, C ^a   Cerny, T ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Ifosfamide; Ketimines; Methylene blue; Mitochondrial drug toxicity; Neurotoxicity

Indexed keywords

ACROLEIN; DRUG METABOLITE; FLAVOPROTEIN; IFOSFAMIDE; MESNA; METHYLENE BLUE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

BRAIN DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MITOCHONDRION; NEUROTOXICITY; NONHUMAN; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ANTIDOTES; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN DISEASES; DRUG THERAPY, COMBINATION; HEPATIC ENCEPHALOPATHY; HUMANS; IFOSFAMIDE; METHYLENE BLUE; OXIDATION-REDUCTION; RATS;

EID: 0030014316     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050102     Document Type: Review

References (40)

1. Cerny T, Küpfer A (1992) The enigma of ifosfamide encephalopathy. Ann Oncol 3:679-681
2. Wagner T, Drings P (1987) Pharmacokinetics and bioavailability of oral ifosfamide. Contr Oncol 26:53-59
3. Manegold C, Bischoff H, Fischer JR, Löchner S, Peukert M, Schmähl A, Drings P (1992) Oral ifosfamide-mesna: a clinical investigation in advanced non-small cell lung cancer. Ann Oncol 3:723-726
4. Kamen BA, Frenkel E, Colvin O (1995) Ifosfamide: should the honeymoon be over? J Clin Oncol 13:307-309
5. Küpfer A, Aeschlimann Ch, Wermuth B, Cerny T (1994) Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 343:763-764
6. Goodman SI, Frerman FE (1989) Glutaric acidemia type II and defects of the mitochondrial respiratory chain. In: Scriver CR, Beaudet AL, Sly WS, Valle D (ed) The metabolic basis of inherited disease. McGraw-Hill, pp 915-931
7. 10-dicarboxylic acids, ethylmalonic acid, 5-hydroxycaproic acid, butyrylglycine, isovalerylglycine, isobutyrylglycine, 2-methylbutyrylglycine and glutaric acid in the urine of riboflavin deficient rats. J Inher Metabol Dis 5 [Suppl 1]:17-18
8. Sherratt HSA (1986) Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit. TIPS 186-191
9. Zulian GB, Tullen E, Maton B (1995) Methylene-blue for ifosfamide-associated encephalopathy. N Engl J Med 332:1239-1240
10. Aeschlimann C, Cerny T, Küpfer A (1994) Chloroethylamine: a urinary metabolite of patients with high dose ifosfamide treatment. Naunyn-Schmiedeberg's Arch Pharmacol 349:R 130
11. Highley MS, Momerency G, van Cauwenberghe K, van Oosterom AT, de Bruijin EA, Maes RAA, Blake P, Mansi J, Harper PG (1995) Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metabol Dispos 23:433-437
12. Jaim-Etcheverry G, Zieher LM (1983) 2-Chloroethylamines: new chemical tools for the study of noradrenergic neurons. TIPS 473-475
13. Küpfer A, Aeschlimann Ch, Wermuth B, Visarius TM, Cerny T (1996) Experimental glutaric aciduria in rats: a new animal model for mitochondrial ifosfamide toxicity in man. Experientia 52:85
14. Cavallini D, Ricci G, Dupre S, Pecci L, Costa M, Matarese RM, Pensa B, Antonucci A, Solinas SP, Fontana M (1991) Sulfur-containing cyclic ketimines and imino acids. A novel family of endogenous products in the search for a role. Eur J Biochem 202:217-223
15. Ricci G, Nardini M, Caccuri AM, Federici G (1983) Interaction between 1,4-thiazine derivatives and d-amino-acid oxidase. Biochem Biophys Acta 748:40-47
16. Pecci L, Montefoschi G, Fontana M, Cavallini D (1994) Ammoethyl-cysteine ketimine decarboxylated dimer inhibits mitochondrial respiration by impairing electron transport at complex I level. Biochem Biophys Res Comm199:755-760
17. Nardini M, Ricci G, Vesci L, Pecci L, Cavallini D (1988) Bovine brain ketimine reductase. Biochem Biophys Acta 957:286-292
18. Nardini M, Ricci G, Caccuri AM, Solinas SP, Vesci L, Cavallini D (1988) Purification and characterization of a ketimine-reducing enzyme. Eur J Biochem 173:689-694
19. 35S)Lanthionine ketimine binding to bovine brain membranes. Biochem Biophys Res Comm 171:480-486
20. Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II:1219-1220
21. Kaijser GP, Bult A, Wiese G, de Kraker J, Keizer HJ, Underberg WJM (1992) Gas chromatographic determination of 2- and 3-dechloroethyl-ifosfamide in plasma and urine. J Chromatogr 583:175-182
22. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42
23. Kaijser GP, Beijnen JH, Jeunink EL, Bult A, Keizer HJ, de Kraker J, Underberg WJM (1993) Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J Chromatogr 614:253-259
24. Sood C, O'Brien PJ (1993) Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 46:1621-1626
25. Sood C, O'Brien PJ (1994) Chloroacetaldehyde-induced hepatocyte cytotoxicity. Biochem Pharmacol 48:1025-1032
26. Zamlauski Tucker MJ, Morris ME, Springate JE (1994) Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 129:170-175
27. Mohrmann M, Ansorge S, Schmich U, Schonfeld B, Brandis M (1994) Toxicity of ifosfamide, cyclopliosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol 8:157-163
28. Hofmann U, Eichelbaum M, Seefried S, Meese CO (1991) Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide and (3-carboxy-methylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. Drug Metabol Dispos 19:222-226
29. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T (1994) Depletion of total cysteine, glutathione and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35:132-136
30. Peters RA (1952) Lethal synthesis. Proc Roy Soc London (Series B) 139:143-170
31. Harpey JP, Charpentier C, Coude M (1986) Methylene-blue for riboflavin-unresponsive glutaricaciduria type II. Lancet I:391
32. Solinas SP, Pecci L, Montefoschi G, Cavallini D (1992) The reducing activity of S-aminoethylcysteine ketimine and similar sulfur-containing ketimines. Biochem Biophys Res Comm 183:481-486
33. Greenberg SR, Kerr JH (1965) Methylene-blue in alcohol-induced hypoglycaemia. Lancet II:1132
34. Madison LL, Lochner A, Wulff J (1967) Ethanol-induced hypoglycemia. Mechanism of suppression of hepatic gluconeogenesis. Diabetes 16:252-258
35. Hrushesky WJM, Olshefski R, Wood P, Meshnick S, Eaton JW (1985) Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet I:565-567
36. Glover V, Reveley MA, Sandler M (1980) A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 29:467-470
37. Neumann R, Hevey R, Abeles RH (1975) The action of plasma amine oxidase on beta-haloamines. J Biol Chem 250:6362-6367
38. Visarius TM, Lauterburg BH, Küpfer A, Stucki JW (1996) Long chain fatty acid oxidation in mitochondria is inhibited by chloroacetaldehyde and restored by methylene blue. Experientia 52:84
39. Salaris SC, Barbs CF, Voorhees III WD (1991) Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. Biochem Pharmacol 42:499-506
40. Cerny T, Lind M, Thatcher N, Swindell R, Stout R (1989) A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer. Br J Cancer 60:258-261